



Retraction notice



Retraction notice to “Use of ivermectin in the treatment of Covid-19: A pilot trial” [Toxicol. Rep. 8 (2021) 505–510]

Henrique Pott-Junior^{a,*}, Mônica Maria Bastos Paoliello^b, Alice de Queiroz Constantino Miguel^c, Anderson Ferreira da Cunha^d, Caio Cesar de Melo Freire^d, Fábio Fernandes Neves^a, Lucimar Retto da Silva de Avó^a, Meliza Goi Roscani^a, Sigrid De Sousa dos Santos^a, Silvana Gama Florêncio Chach^a

^a Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil

^b Department of Molecular Pharmacology, Albert Einstein College of Medicine, 10461 Bronx, NY, United States

^c University Hospital of the Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil

^d Department of Genetics and Evolution, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil

This article has been retracted: please see Elsevier Policy on Article Withdrawal (<https://www.elsevier.com/about/our-business/policies/article-withdrawal>).

The article has been retracted at the request of the Founding Editor, Prof. Lawrence H. Lash, on the basis that there is clear evidence that the findings are unreliable: <https://publicationethics.org/files/retraction-guidelines-cope.pdf>.

Additional external review of this published paper raised several concerns. While a properly conducted clinical trial is certainly welcome, the experimental design of this study lacks sufficient details for some of the methods and approaches, uses inappropriate or inadequate

statistical analysis, and presents unclear data interpretation.

The conclusions and statements of the authors cannot be readily supported by the information presented in the paper.

Additionally, no reference is made to the well-known controversies that surrounded the recommended use of ivermectin to treat infections with COVID-19. <https://www.nature.com/articles/d41586-02-0-01695-w>; <https://www.the-scientist.com/news-opinion/surgisphere-sows-confusion-about-another-unproven-covid19-drug-67635> The omission of any discussion of these controversies in the present paper makes the paper misleading and unacceptable.

DOI of original article: <https://doi.org/10.1016/j.toxrep.2021.03.003>.

* Corresponding author.

E-mail address: henriquepott@ufscar.br (H. Pott-Junior).

<https://doi.org/10.1016/j.toxrep.2022.04.009>